saxenda glp-1 pharmaceutical company overview The Multi-Sector Impacts of GLP-1RA Drugs FDA Approves First Generic GLP-1

The incidence of hypoglycemia was 0.6% in patients given placebo, 0.6% in patients given sitagliptin alone, 0.8% in patients given metformin alone, and 1.6% in patients given sitagliptin in combination with metformin

[Abstract]2024 Aug;14(8):3493-3512

Neumiller JJ, Bajaj M, Bannuru RR, McCoy RG, Pekas EJ, Segal AR, et al

However, the drug is not a short-term weight loss option to be used multiple times or to lose a few pounds every so often

The full analysis set of all randomized individuals and the safety analysis set (all individuals receiving at least one dose of trial product) were the same and therefore used for all efficacy and safety evaluations